CG Oncology Inc. has successfully completed the enrollment of patients in their BOND-003 Phase 3 monotherapy study. This study aims to evaluate the effectiveness of cretostimogene grenadenorepvec as a potential treatment for high-risk non-muscle invasive bladder cancer (NMIBC) patients who do not respond to Bacillus Calmette-Guerin (BCG).
The BOND-003 study has enrolled a total of 110 patients with BCG-Unresponsive High-Risk NMIBC across North America and the Asia-Pacific regions. The primary goal of this study is to determine the complete response (CR) rate at any time, while secondary objectives include assessing CR at 12 months, duration of response, progression-free survival, cystectomy-free survival, and safety.
Andrea-Maddox Smith, CEO of the Bladder Cancer Advocacy Network (BCAN), expressed her excitement about the availability of new treatments for bladder cancer patients with BCG-unresponsive disease. She highlighted that currently, these patients have limited options and may only consider bladder removal as a treatment choice.